The regulation, capital and partnerships reshaping health across the GCC. Saudi Arabia's $34.6bn biotech mandate, read from inside the room.
Every regulatory move, tender, partnership and capital flow across Gulf life sciences, read for what it opens up.
Lifera's SaudiBio is localising insulin manufacture with Novo Nordisk. Every localisation mandate opens a named partner slot for a manufacturer willing to transfer technology.
Lifera ↗Global investors supplied 49% of capital across 688 deals, with funding up 74% on 2024.
MAGNiTT ↗The SFDA's MDS-G53 sets the evidence bar. Software that reads patient data has a named route to authorisation.
Emergo by UL ↗The mandates and flows behind the build. Every figure here is sourced, not estimated.
Tracks the mandates, capital and regulation reshaping Gulf health. The layer the whole ecosystem reads from.
You Are HereTakes international biotech and medtech into the Kingdom, from the regulatory file to the route to market.
Explore A7i Partners ↗ DistributionPlaces wellness, functional food and ingredient brands across Saudi retail, pharmacy and hospitality.
Explore A7i Wellness ↗Operators, regulators and founders building Gulf health, in long form. Launching on Spotify, Apple Podcasts and YouTube.
First guests from across the SFDA, Gulf biotech and the founders building inside the Kingdom. Be first to hear it.
The Gulf holds the long view. The energy infrastructure that powers global industry is now matched by the scientific and clinical capability that will shape human health. The region is investing at scale and partnering on its own terms.
That ambition deserves reporting by people who operate inside it. A7i Intelligence tracks what the region is building, and what each move opens up.
The door is open.
Leads A7i's commercial strategy, partner selection and international origination. Based between Riyadh and Melbourne, she runs the corridor into Saudi Arabia from both ends.
Leads in-Kingdom execution, government engagement and partner operations. Saudi-born and based in the Kingdom, with direct relationships across senior government and major institutional health buyers.
Thirty-five years across the Saudi healthcare system, former Head of Home Medical Care at King Fahd General Hospital, Jeddah. Advises A7i on clinical fit and the operating context inside the Kingdom.
The questions executives, investors and founders ask about the Gulf life sciences market.
Biotechnology sits at the centre of Vision 2030's push to diversify the economy beyond oil. The National Biotechnology Strategy targets a $34.6bn contribution to non-oil GDP by 2040 across four pillars: vaccines, biomanufacturing, genomics and plant optimisation. The aim is to localise healthcare and manufacturing, build precision-medicine and genomics capability, and strengthen food security. A7i Intelligence tracks each mandate, tender and investment as it moves.
The clearest openings are in pharmaceutical manufacturing and localisation, diagnostics and medical devices, precision medicine and genomics, digital health, and wellness and functional food. Saudi localisation mandates open named partner slots for manufacturers willing to transfer technology, as with Lifera's CDMO deals with Novo Nordisk, Pfizer and Jamjoom Pharma. A7i Intelligence reports these openings as they surface.
A7i Intelligence reports on government mandates, capital flows, regulatory developments, manufacturing, partnerships and emerging companies across the GCC. The Wire feed carries developments as they happen, and the weekly newsletter reads them for what each one opens up.
It is the Kingdom's plan to build a biotech economy around four pillars: vaccines, biomanufacturing, genomics and plant optimisation. It targets a $34.6bn contribution to non-oil GDP by 2040 and underpins much of the localisation and manufacturing activity A7i Intelligence covers.
A foreign manufacturer without a Saudi legal entity must appoint an SFDA authorised representative to hold its product registrations and act as the regulatory point of contact. From there, entry runs through registration, distribution and buyer access. A7i Partners acts as the operating partner across that path.
The Saudi Food and Drug Authority regulates medicines, medical devices, food and supplements in the Kingdom. It sets the registration and evidence requirements every product must meet, including a defined pathway for AI-enabled medical devices under MDS-G53. No product reaches the Saudi market without clearing it.
The Hevolution Foundation, based in Riyadh, has committed more than $400m to aging research and backs the $101m XPRIZE Healthspan, the largest longevity prize to date. It is one of the most active funders of healthspan science globally.
Yes. The Gulf Biotech Brief brings operators, regulators and founders building Gulf health into long-form conversation. Season one is recording now, launching on Spotify, Apple Podcasts and YouTube.
The regulatory moves, tenders, partnerships and capital flows that matter, and what each one opens up. Weekly at launch.
No spam. Unsubscribe in one click.
For partnership, editorial and press enquiries, and for companies weighing Gulf entry who want a direct line to the desk. Ready to enter now? Start with A7i Partners.